White label ELPA - ClinicalTrials.eu

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Recruiting

3 1
Investigated diseases:
- Systemic lupus erythematosus
Investigated drugs:
- Nipocalimab
+9
RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Recruiting

3 1

+2
ICP-332 for Adults with Prurigo Nodularis

Recruiting

2 1
Investigated diseases:
- Neurodermatitis
Investigated drugs:
- 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE
Study on Stem Cell Treatment for Venous Ulcers in the Legs Using Bioengineered Artificial Mesenchymal Sheet (BAMS)

Recruiting

1 1 1
Investigated diseases:
- Skin ulcer
Investigated drugs:
- Allogenic Adipose-Derived Adult Mesenchymal Stem Cells Expanded On Fibrin-Hyaluronic Biological Matrix
Study on Brimonidine Eye Drops to Prevent Myopia Progression in Children Aged 6 to 14 Years

Recruiting

2 1 1 1
Investigated diseases:
- Myopia
Investigated drugs:
- Brimonidine Tartrate
One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

Recruiting

3 1 1
Investigated diseases:
- Crohn’s disease
Investigated drugs:
- Guselkumab
Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

Recruiting

3 1 1 1
Investigated drugs:
- Fludarabine Phosphate
Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

Recruiting

3 1 1
Investigated drugs:
- Thiocolchicoside
- Paracetamol
Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes

Recruiting

3 1
Investigated diseases:
- Obesity
+2
A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

Recruiting

2 1 1 1
Investigated diseases:
- Hormone receptor positive HER2 negative breast cancer
- Neoplasm malignant
Investigated drugs:

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies